Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flu Hunters: House Committee Searches For Pandemic Plan

Executive Summary

Update to 2005 outline of US response to pandemic influenza was due at the end of 2016, but has yet to be released.

You may also be interested in...



IPO Update: Three Biopharma Offerings In January Contrast With Last Year’s Slow Start

AnaptysBio, Jounce and ObsEva were the first three companies to go public in 2017 – all in January – while no therapeutics firms went public in January 2016. The difference? Better US biopharma stock performance.

FDA's Document Dump: Guidance Release Skyrockets Ahead Of Trump's Arrival

Uncertainty about US FDA's direction under the new president may have spurred staff to ensure views on several issues released before administration changed.

The Trump Administration: Seven More Things To Watch Out For

Beyond pricing, industry experts weigh in on how the next administration has shifted expectations across a range of areas – including tax reform, FDA standards and the Cancer Moonshot Initiative.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS120475

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel